Stock Markets February 2, 2026

60 Degrees Pharmaceuticals Shares Slide After GoodRx Deal to Offer Discounts on ARAKODA

Partnership will allow eligible patients to receive up to 30% savings on tafenoquine at pharmacies and by home delivery starting Feb. 2, 2026; stock fell sharply in premarket trading

By Jordan Park SXTP GDRX
60 Degrees Pharmaceuticals Shares Slide After GoodRx Deal to Offer Discounts on ARAKODA
SXTP GDRX

60 Degrees Pharmaceuticals said it has partnered with GoodRx to provide eligible consumers savings of up to 30% on ARAKODA (tafenoquine), the only FDA-approved once-weekly malaria prevention drug on the U.S. market, beginning February 2, 2026. The announcement preceded a 16.9% drop in the company's stock in premarket trading. The program will expand discounted access through more than 70,000 pharmacies and home delivery when available.

Key Points

  • 60 Degrees Pharmaceuticals partnered with GoodRx to offer eligible consumers up to 30% savings on ARAKODA starting February 2, 2026.
  • Discounted pricing will be available at over 70,000 pharmacies nationwide and via home delivery when available, expanding potential patient access to the only FDA-approved once-weekly malaria prevention drug in the U.S.
  • The partnership announcement coincided with a 16.9% drop in 60 Degrees Pharmaceuticals' stock price in premarket trading, signaling an immediate negative market reaction; sectors impacted include pharmaceuticals, retail pharmacy distribution, and travel-related pharmaceutical demand.

60 Degrees Pharmaceuticals Inc reported a strategic collaboration with GoodRx that will make discounted pricing available for its malaria prevention medication ARAKODA (tafenoquine). The company said eligible consumers can receive savings of up to 30% on the prescription drug, with access beginning February 2, 2026.

The arrangement will allow patients to obtain ARAKODA at over 70,000 pharmacies nationwide through GoodRx’s platform, or to have the drug delivered to their homes when delivery is available, according to the announcement. ARAKODA is described as the only FDA-approved, once-weekly prescription medication for malaria prevention currently on the U.S. market.

Following the release of the partnership details, 60 Degrees Pharmaceuticals' stock experienced a marked decline, falling 16.9% in premarket trading on Monday. The company, which focuses on developing therapies for vector-borne diseases, did not provide additional guidance in the announcement accompanying the GoodRx collaboration.

ARAKODA, whose active ingredient is tafenoquine, was discovered by the Walter Reed Army Institute of Research and received FDA approval in 2018. The drug is primarily prescribed for travelers who are headed to regions where malaria is endemic. Clinically, the medicine is notable for a long terminal half-life of approximately 16 days, which supports less-frequent dosing compared with some alternative malaria prophylaxis options.

The standard dosing schedule for ARAKODA consists of a loading phase and a maintenance phase: two 100mg tablets taken daily for three days prior to travel; followed by two 100mg tablets taken weekly while traveling, for up to six months; and concluding with two 100mg tablets in the week after travel.

Company officials framed the GoodRx arrangement as a means to expand discounted access to ARAKODA for eligible consumers, while market participants reacted negatively in early trading. The announcement leaves certain execution details - such as the scope of eligibility and the timing and availability of home delivery - subject to the terms described in the partnership notice.


Summary

  • 60 Degrees Pharmaceuticals formed a partnership with GoodRx to offer up to 30% savings on ARAKODA starting Feb. 2, 2026.
  • The program will make discounts available at more than 70,000 pharmacies and via home delivery when available.
  • Following the announcement, the company's stock fell 16.9% in premarket trading.

Risks

  • Stock volatility: the company's shares fell 16.9% in premarket trading following the partnership announcement, indicating potential market sensitivity to strategic news.
  • Execution uncertainty: home delivery is conditional 'when available,' and the announcement did not detail eligibility criteria or rollout specifics, leaving questions about the program's immediate reach.
  • Demand uncertainty: while the partnership aims to increase affordability, the effect on actual prescribing patterns and sales was not disclosed, creating uncertainty for pharmaceutical and retail pharmacy revenue expectations.

More from Stock Markets

Quarantine Enforced at Texas Immigration Center After Two Measles Cases Confirmed Feb 2, 2026 Security Flaw in 'Moltbook' Exposed Private Data of Thousands, Cyber Firm Says Feb 2, 2026 Capgemini to Divest U.S. Government Unit Amid Scrutiny Over ICE Contract Feb 2, 2026 Piper Sandler Favors Select Home Improvement Names as Home Equity Activity Rebounds Feb 2, 2026 Ondas to Buy Rotron Aero, Expanding Long-Range Autonomous Strike Capabilities Feb 2, 2026